Sanofi appoints its first chief digital officerSanofi has become the latest big pharma firm to appoint a chief digital officer, choosing Ameet Nathwani to Share XSanofi appoints its first chief digital officerhttps://pharmaphorum.com/news/sanofi-appoints-its-first-chief-digital-officer/
Pharma companies clear the R&D decks in Q4The fourth-quarter results season has already seen a host of unwanted projects cleared from pharma companies’ pipelines as Share XPharma companies clear the R&D decks in Q4https://pharmaphorum.com/news/pharma-companies-clear-the-rd-decks-in-q4/
Sanofi expects growth as rare disease drugs boost earningsSanofi’s strategy of betting on new drugs and biotech acquisitions seems to be paying off, as the company Share XSanofi expects growth as rare disease drugs boost earningshttps://pharmaphorum.com/news/sanofi-expects-growth-as-rare-disease-drugs-boost-earnings/
Sanofi’s Darzalex rival hits the mark in phase 3 trialJohnson & Johnson’s Darzalex multiple myeloma drug has just become a blockbuster – but it could face competition Share XSanofi’s Darzalex rival hits the mark in phase 3 trialhttps://pharmaphorum.com/news/sanofis-darzalex-rival-hits-the-mark-in-phase-3-trial/
NHS faces uphill battle in prevention – surveyA new survey has revealed confusion amongst the UK public on how to maintain a healthy lifestyle, suggesting Share XNHS faces uphill battle in prevention – surveyhttps://pharmaphorum.com/news/nhs-uphill-battle-prevention-survey/
FDA advisers divided on Sanofi’s oral type 1 diabetes drugThe future of Sanofi and Lexicon’s oral diabetes drug Zynquista hangs in the balance after an FDA advisory Share XFDA advisers divided on Sanofi’s oral type 1 diabetes drughttps://pharmaphorum.com/news/fda-divided-on-sanofis-oral-type-1-diabetes-drug/
Sanofi gets opt-in rights to two Regeneron cancer drugsSanofi and Regeneron have restructured and extended their immune-oncology discovery and development agreement, giving the French drugmaker rights Share XSanofi gets opt-in rights to two Regeneron cancer drugshttps://pharmaphorum.com/news/sanofi-gets-opt-in-rights-to-two-regeneron-cancer-drugs/
Praluent not worth the price, finds studySanofi and Regeneron’s Praluent may still not be cost effective compared to other cholesterol-lowering drugs despite a recent Share XPraluent not worth the price, finds studyhttps://pharmaphorum.com/news/praluent-not-worth-the-price-finds-study/
Sanofi palms off MyoKardia heart disease pactSanofi has walked away from a four-year-old alliance with US biotech MyoKardia, handing back rights to three drugs Share XSanofi palms off MyoKardia heart disease pacthttps://pharmaphorum.com/news/sanofi-palms-off-myokardia-heart-disease-pact/
